Brendan Hannah has served as Quince’s Chief Operating Officer since October 2023, its Chief Business Officer since May 2022, and is currently the company’s Principal Financial Officer. To this role, he brings 15 years of corporate development, operational, finance, and company formation experience.
Previously, Mr. Hannah was Chief Operating Officer at Novosteo where he led the company’s operational and finance activities, including business development, commercial strategy, financial planning and analysis, and investor relations. Previously, he was Chief Business Officer at Neuroptika where he led business operations and global R&D for a nerve regenerative therapeutic spanning advancement from preclinical studies through Phase 2 study. Prior to that, Mr. Hannah was Head of Corporate Development at Agenovir, a CRISPR/Cas company focused on eliminating viral reservoirs where he led the acquisition of Agenovir by Vir Bio for up to $290 million. Previously, he was Director of Business Development at Cidara Therapeutics (CDTX). He started his career in business development at Trius Therapeutics (TSRX) where he had increasing roles of responsibility, culminating in his group leading an acquisition by Cubist Pharmaceuticals valued at more than $700 million upfront.
Mr. Hannah received a M.B.A. with honors from University of California, Los Angeles, Anderson School of Management and received a B.A. in Economics from Colorado College.
What is Brendan Hannah's net worth?
The estimated net worth of Brendan Hannah is at least $22.55 thousand as of August 19th, 2024. Mr. Hannah owns 1,298 shares of Quince Therapeutics stock worth more than $22,546 as of July 1st. This net worth approximation does not reflect any other assets that Mr. Hannah may own. Learn More about Brendan Hannah's net worth.
How do I contact Brendan Hannah?
Has Brendan Hannah been buying or selling shares of Quince Therapeutics?
Brendan Hannah has not been actively trading shares of Quince Therapeutics during the last ninety days. Most recently, on Wednesday, August 21st, Brendan Hannah bought 154 shares of Quince Therapeutics stock. The stock was acquired at an average cost of $126.00 per share, with a total value of $19,404.00. Following the completion of the transaction, the chief operating officer now directly owns 1,482 shares of the company's stock, valued at $186,732. Learn More on Brendan Hannah's trading history.
